CSIMarket Company Name, Ticker, Industry, else..
 
Nkgen Biotech Inc   (NKGN)
 
Price: $0.0020 $0.00 0.000%
Day's High: $0.0020000000949949026 Week Perf: 0.00
Day's Low: $ 0.00 30 Day Perf: -60 %
Volume (M): 0 52 Wk High: $ 0.33
Volume (M$): $ 0 52 Wk Avg: $0.05
Open: $0.00 52 Wk Low: $0.00



 Market Capitalization (Millions $) 0
 Shares Outstanding (Millions) 103
 Employees 26
 Revenues (TTM) (Millions $) -
 Net Income (TTM) (Millions $) 17
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0

Business Description


Nkgen Biotech Inc is a biotechnology company that focuses on developing novel treatments for cancer and other life-threatening diseases. They specialize in utilizing natural killer (NK) cells, a type of immune cell, for therapeutic purposes. Nkgen Biotech Inc is known for its innovative research and development of NK cell-based therapies, including CAR-NK cell therapies which involve genetically modifying the NK cells to enhance their tumor-killing abilities. The company is committed to improving patient outcomes and revolutionizing the field of cancer treatment with their groundbreaking approaches.


   Company Address: 3001 Daimler Street Santa Ana 92705 CA
   Company Phone Number: 396-6830   Stock Exchange / Ticker: NKGN


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ALEC   -12.38%    
ARMP   -20.27%    
FATE        6.87% 
MRNA        15.94% 
NVAX        9.03% 
STRO   -14.13%    
• View Complete Report
   



Partnership

Strategic Partnership Aims to Advance Novel NK Cell Therapy in Japan

Published Fri, Jul 18 2025 11:35 AM UTC

In a notable development in the field of biotechnology, NKGen Biotech and HekaBio have announced a strategic partnership aimed at advancing the development and commercialization of an innovative autologous NK cell therapy named troculeucel in Japan. This collaboration is anchored by a recent strategic investment made by HekaBio in NKGen Biotech, underscoring the commitment o...
Clinical Study

Advancements in Troculeucel Therapy A Potential Breakthrough for Post-Stroke and Alzheimer’s Patients

Published Fri, Jun 20 2025 5:12 PM UTC

Abstract: NKGen Biotech is at the forefront of developing innovative cellular therapies, including Troculeucel, which shows promise in treating post-stroke and Alzheimer’s disease (AD) patients. Recent advancements include the administration of Troculeucel to a stroke patient under an FDA-cleared compassionate use program and positive Phase 1 clinical trial results demonst...
Clinical Study

Navigating Promise and Peril NKGen Biotechs Dual Journey in FTD Treatment Innovation and Financial Realignment,

Published Fri, Feb 21 2025 5:45 PM UTC

Emerging Therapeutic Frontier: NKGen Biotech s Innovative Step Forward in Frontotemporal Dementia Treatment Amid Financial Challenges NKGen Biotech Inc. a company immersed in the cutting-edge landscape of biotechnology, has taken a meaningful stride in the pursuit of emerging therapeutic solutions with the announcement of the first dose administration of Troculeucel to a fro...
Clinical Study

Evolving Treatment NKGen Biotechs Promising Advances in Alzheimers and Solid Tumor Therapies

Published Thu, Sep 12 2024 12:06 PM UTC

Recent developments from NKGen Biotech highlight significant strides in the treatment of two major health challenges: moderate Alzheimer s disease (AD) and advanced solid tumors. The company s innovative approach, leveraging natural killer (NK) cell therapies, stands out in an increasingly competitive biotech landscape. With pivotal Phase 1 clinical data indicating potential...
Clinical Study

Pioneering Progress NKGen Biotechs Breakthroughs in NK Cell Therapies for Alzheimers and Solid Tumors

Published Tue, Jul 30 2024 12:05 PM UTC

NKGen Biotech, a forward-thinking clinical-stage biotechnology company, is making significant strides in the field of natural killer (NK) cell therapies, positioning itself as a key player in the evolving landscape of cancer treatment and neurodegenerative disease management. This article synthesizes recent advancements showcased by NKGen at notable conferences, particularly...



Fundamental Analysis

Valuation Current
Price to Earnings PE Ratio (TTM) -
Price to Earnings PE Ratio (Expected) -
Price to Sales (TTM) 0.02
Price to Sales (Expected) -
Price to Book -
PEG (TTM) -

Financial Strength Current
Quick Ratio 0
Working Capital Ratio 0.05
Leverage Ratio (MRQ) -
Total Debt to Equity -
Interest Coverage (TTM) 252.99
Debt Coverage (TTM) 1.56

Per Share Current
Earnings (TTM) -1.57 $
Revenues (TTM) 0.1 $
Cash Flow (TTM) -
Cash 0 $
Book Value -
Dividend (TTM) 0 $

Efficiency Current
Revenue per Employee (TTM) -
Net Income per Employee (TTM) 655,731
Receivable Turnover Ratio (TTM) -
Inventory Turnover Ratio (TTM) -
Asset Turnover Ratio (TTM) -

Profitability Ratios Current
Gross Margin (MRQ) -
Operating Margin (MRQ) -
Net Margin (MRQ) -
Net Cash Flow Margin (MRQ) -
Effective Tax Rate (TTM) -

Management Effectiveness Current
Return On Assets (TTM) 108.74 %
Return On Investment (TTM) -
Return On Equity (TTM) -
Dividend Yield -
Pay out Ratio (TTM) -






Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.